Menu

Swedish Research Council: Macchiarini, Karolinska Skipped Ethical Review

The federal agency publishes a brief note alleging another ethical breach by former Karolinska Institute researcher Paolo Macchiarini.

May 3, 2016
Bob Grant

WIKIMEDIA, IJNMIS01A Swedish law in place since January 2004 regarding research conducted on human beings (including living people, cadavers, biological material from people, and sensitive personal information) requires that investigators conducting such work apply for ethical review. According to Anna Hörnlund, chief legal counsel at the Swedish Research Council, neither former Karolinska Institute researcher Paolo Macchiarini nor his former institution submitted an application before conducting such research. “The Swedish Research Council considers Paolo Macchiarini's activities to be research conducted in human beings,” Hörnlund wrote in The Lancet last week (April 30).

Also last week (April 28), the Karolinska Institute announced that it is investigating concerns about Macchiarini and colleagues’ 2015 Respiration paper on the administration of an experimental cellular treatment on a patient with acute respiratory distress syndrome. “I received the case on my desk last week. We have analyzed it and will demand answers from the researchers involved,” Henrik Grönberg, pro-vice-chancellor of the Karolinska Institute, said in the statement. “After that, we will decide if we will submit the matter for external review.”

Some of Macchiarini’s coauthors on a 2011 The Lancet paper last month asked to have their names removed from that study. The Karonliska Institute terminated its contract with Macchiarini in March.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.